Table 5.

Mean (SD) plasma pharmacokinetics a

TH-302 dose, mg/m2TH-302Br-IPM
Terminal half-life, hCmax, μg/mLAUC, μg h/mLTerminal half-life, hCmax, μg/mLAUC, μg h/mL
120 (N = 3)0.83 (0.09)4.2 (0.6)3.9 (1.3)0.81 (0.06)0.06 (0.02)0.08 (0.03)
240 (N = 2)0.98 (0.12)14.7 (11.2)8.4 (4.6)0.46 (0.03)0.11 (0.03)0.11 (0.03)
480 (N = 6)0.98 (0.23)22.5 (9.7)14.5 (4.1)0.54 (0.12)0.15 (0.04)0.16 (0.05)
575 (N = 12)0.83 (0.29)14.7 (9.2)14.1 (4.6)0.67 (0.14)0.19 (0.05)0.26 (0.08)
670 (N = 17)0.84 (0.15)19.7 (7.7)23.0 (7.7)0.87 (0.45)0.22 (0.08)0.37 (0.17)
940 (N = 5)0.80 (0.16)21.2 (5.5)25.8 (8.1)0.61 (0.11)0.37 (0.07)0.54 (0.19)
  • aEstimates are averages of cycle 1, day 1 and cycle 1, day 15 values.